Yahoe schreef:
Dit kwam ik tegen op Yahoo.
Klopt dit?
The royalties from the ATryn approval are hugely unimportant as the EMEA permit applies to the very rare (inherited) case. The approval is mostly symbolic/academic achievement, not a significant source of revenue. GTCB scrambled to get 15 or so participates in the PIII trials and had to enlist pregnant women to compensate the lack of patients!
The LEO led trilas for the other applications are not coming any time soon (2006), nor are the US trials. And a lot of bad things WILL HAPPEN TO THE MARKETS in the meanwhile.
I still think Geoff Cox knows better than you that his company will need to get cash via inevitable dilution. Listen to the year-end CC!